Michael M. Abecassis's most recent trade in PharmaCyte Biotech Inc was a trade of 63,233 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech Inc | Michael M. Abecassis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 63,233 | 63,233 | - | - | Stock Option (Right to Buy) | |
| PharmaCyte Biotech Inc | Michael M. Abecassis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 37,500 | 39,167 | - | 0 | Common Stock | |
| PharmaCyte Biotech Inc | Michael M. Abecassis | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. | 25 Apr 2025 | 16,875 | 22,292 | - | 1.0 | 17,213 | Common Stock |
| PharmaCyte Biotech Inc | Michael M. Abecassis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 38,009 | 38,009 | - | - | Stock Option (Right to Buy) |